Previous iterations of the codec narrative have produced predictable outcomes with incremental efficiency gains, gradual deployment, and long-tail coexistence with previous standards. The same is ...
Editors Tyler H. Walk and Anne Alvergue explain how they cut Sundance-winning documentary Who Killed Alex Odeh?, from ...
NextGen TV is no longer a theoretical upgrade. Across local markets, ATSC 3.0 is moving from early experimentation into a more complex, uneven phase defined by infrastructure choices, receiver ...
OSAKA, Japan & CAMBRIDGE, Mass., February 10, 2026--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) ...
The MarketWatch News Department was not involved in the creation of this content. -- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents, and adults. It is ...
Takeda ( TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the ...
This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment Options Oveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and ...
NT1 is a chronic, rare neurological disease caused by a loss of orexin and characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle tone). This results in a spectrum of ...
The sBLA has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of May 24, 2026. In November 2025, an application for a subcutaneous injectable formulation in ...
A manager at a state-owned enterprise based in Fuzhou, capital of East China's Fujian Province, surnamed Zheng, opened his digital yuan wallet app on Tuesday and noticed an interest rate of 0.05 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results